Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scan surveillance trial launches for HER2+ breast cancer patients

NCT ID NCT07503717

First seen Apr 14, 2026 · Last updated Jun 15, 2026 · Updated 11 times

Summary

This study looks at whether it's possible to routinely scan the brains of people with HER2-positive metastatic breast cancer to find cancer spread early. About 69 participants will get a baseline brain MRI, and if no brain tumors are found, they'll be randomly assigned to either follow-up scans or standard care. The goal is to see if patients are willing to join and if early detection improves outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beaumont RCSI Cancer Centre

    RECRUITING

    Beaumont, Ireland

    Contact Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.